Zentalis Pharmaceuticals Inc

NASDAQ:ZNTL   4:00:00 PM EDT
23.29
-1.23 (-5.02%)
6:24:36 PM EDT: $23.76 +0.47 (+2.02%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Zentalis Pharmaceuticals Inc Stock, NASDAQ:ZNTL

1359 Broadway, Suite 1710, New York, New York 10018
United States of America
Phone: +1.212.433.3791
Number of Employees: 177

Description

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.